Cocrystal Pharma (NASDAQ:COCP) Shares Cross Above 200 Day Moving Average – Should You Sell?

Shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.10 and traded as high as $1.14. Cocrystal Pharma shares last traded at $1.1050, with a volume of 62,169 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have commented on COCP shares. Weiss Ratings downgraded shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. HC Wainwright reiterated a “buy” rating on shares of Cocrystal Pharma in a research note on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cocrystal Pharma has an average rating of “Hold”.

Cocrystal Pharma Stock Performance

The stock has a fifty day moving average of $1.09 and a 200 day moving average of $1.10. The company has a market capitalization of $19.65 million, a P/E ratio of -1.34 and a beta of 1.60.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.10 million. Research analysts anticipate that Cocrystal Pharma, Inc. will post -0.69 EPS for the current fiscal year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics. The company uses structure-based drug discovery and advanced medicinal chemistry to design small-molecule treatments intended to target viral replication mechanisms. Cocrystal’s research and development programs have focused primarily on infectious diseases, including influenza A and norovirus. Its pipeline has included orally administered antiviral candidates designed to inhibit viral polymerase proteins, as well as programs addressing other significant viral pathogens.